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Abstract Shiga toxin-producing Escherichia coli (STEC)
may cause haemolytic uraemic syndrome (HUS).
Age ≤5 years and presence of stx2a and eae are risk factors
for the development of HUS. In this study, we investigated
STEC isolates for the presence of adhesins, toxins and molec-
ular risk assessment (MRA) factors to identify virulence genes
associated with HUS development. We included non-
duplicate isolates from all STEC infections (n = 340,
HUS = 32) reported to the Norwegian National Reference
Laboratory (NRL) for Enteropathogenic Bacteria from 1992
to 2013. The most common STEC were O157:H7/H− (34%)
and O103:H2 (14%). We retrospectively screened the isolates
by three multiplex polymerase chain reactions (PCRs) for
adhesins (n = 11), toxins (n = 5) and MRA (n = 15). We
calculated odds ratios (ORs) and adjusted odds ratios (aORs)
for associations with HUS development. On average, isolates
were positive for 15 virulence genes (range: 1–24); two toxins
(range: 0–4), five adhesins (range: 0–8) and eight MRA genes
(range: 0–13). The gene combinations were clustered within
serotypes. Isolates from HUS cases were positive for eae and
IpfAO26, and negative for saa, eibG, astA, cnf, subA and pic.
We identified 11 virulence genes with a significant association
to HUS development. Multivariable analyses adjusted for age
group and Shiga toxin identified nleH1–2 [aOR 8.4, 95%
confidence interval (CI); 2.18–32.3] as an independent risk
factor for the development of HUS from an STEC infection.
This study demonstrated that the non-LEE effector protein
nleH1–2 may be an important predictor for elevated risk of
developing HUS from STEC infections. We recommend the
NRL for Enteropathogenic Bacteria to consider including
nleH1–2 screening as part of routine STEC surveillance.
Introduction
Shiga toxin-producing Escherichia coli (STEC) is a zoonotic
food- and waterborne pathogen of a serious public health con-
cern because of its propensity to cause outbreaks,
haemorrhagic colitis and the potentially life-threatening com-
plication haemolytic uraemic syndrome (HUS) [1, 2]. It is
estimated that 6–25% of patients infected with STEC develop
HUS, with up to 50% requiring renal dialysis. In children, this
rate is much higher [1]. HUS generally complicates 6–9% of
STEC infections overall and about 15% of infections in chil-
dren, with mortality of 2–5% and up to 30% developing long-
term sequelae [2, 3]. Currently, there are no available treat-
ments for HUS and prevention strategies are limited.
The production of bacteriophage-encoded Shiga toxin 2a
(Stx2a) by STEC is the primary virulence trait responsible for
HUS development, along with the presence of intimin (eae)
and young age of the host (≤5 years old) [4–6]. However, not
all cases of STEC infections harbouring these characteristics
develop HUS. The clinical significance of STEC for humans
is further determined by the production and interplay of
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additional virulence factors, as well as host factors such as
immunocompetence [7, 8].
Typically, STEC strains harbour the genomic island termed
the ‘locus of enterocyte effacement’ (LEE), which encodes
genes that facilitate the colonisation process (e.g. eae). The
LEE also encodes a series of proteins that induce cytoskeletal
changes in the eukaryotic target cell to enhance attachment
and effacement of the bacterium [9, 10]. In addition, many
vi ru lence fac tors , such as the plasmid-encoded
enterohaemolysin (ehxA), have been shown to be important
for the pathogenicity of STEC. A number of candidate path-
ogenicity islands (PAIs), including OI-122 and OI-71, encode
a variable repertoire of non-LEE-encoded effector (nle) pro-
teins which are present in many STEC strains. However, their
role in disease development is not yet fully understood [8, 11,
12].
Recently, we published a comprehensive study spanning
20 years from 1992 to 2012, where we investigated host fac-
tors such as age, sex and clinical manifestations, and strain
factors such as serotypes, stx types and the presence of eae and
ehxA, with the association of developing HUS from STEC
infections in Norway [5]. Following in line with the concept
of a molecular risk assessment (MRA) [13], the objective of
this study was to identify virulence factors important for HUS
development, to enable an improved differentiation of HUS-
associated STEC from low virulent STEC infections and ex-
pand the Norwegian STEC surveillance system.
Methods
Case definition, strain and data collection
An STEC infection was defined as the isolation of an STEC
from a clinical sample. We retrospectively included all non-
duplicate STEC isolates, one isolate per outbreak (unless dif-
ferent virulence gene profiles were detected), submitted to the
National Reference Laboratory (NRL) for Enteropathogenic
Bacteria from 1992 to 2012 (n = 334). In addition, we includ-
ed all STEC isolates recovered from HUS patients in Norway
in 2013 (n = 6). HUS was defined as acute renal failure within
14 days of an episode of acute diarrhoea with either microan-
giopathic haemolytic anaemia or thrombocytopaenia. Clinical
and epidemiological information of cases corresponding to the
selected STEC isolates were retrieved from the Norwegian
Surveillance System for Communicable Diseases database.
Serotyping
All isolates were consecutively serotyped at the NRL on re-
ception using slide agglutination against 43 different O
groups, fliC-PCR for H groups and wzx- and wzy-PCR for
14 O groups for non-agglutinating isolates, as described pre-
viously [5].
Sorbitol-fermenting (SF) E. coli O157
Isolates belonging to serogroup O157 were analysed for sor-
bitol fermentation by polymerase chain reaction (PCR) as de-
scribed previously [5].
Virulence genes characterisation
All isolates were consecutively screened for the presence of
genes stx1a, c, d, stx2a–g, eae and ehxA by PCRs, as de-
scribed previously [5]. In addition, all isolates were retrospec-
tively screened for five toxin genes (cnf, astA, subA, StcE/
StcEO103, cdtB I–IV), 11 adhesin genes (saa, ihaA,
agn43EDL933, Ipf1O157/OI-141, IpfAO26, Ipf2O157/OI-154,
IpfAO113, eibG, toxB, espP, ehaA) and 15 genes previously
classified as MRA genes [14–18] (aaiC, fyuA, ent/espL2n,
nleB, nleE, efa1/lifA, pagC-like, nleH1–2, ureC, nleC, ecf4,
paa, pic, nleG2–3, Z2099) using three multiplex PCRs. For all
PCRs, DNA was extracted by boiling, primers were 5′ end
labelled (6-FAM, VIC or PET), and PCRs were run and
analysed as described previously (Supplemental Table 3) [19].
Clustering and statistics
We performed cluster analysis with the presence and absence
of 33 virulence genes and subtypes of stx1 and stx2 in
BioNumerics v.7.6 (Applied Maths, Belgium) using an un-
weighted pair group method with arithmetic mean
(UPGMA) for phylogeny. Statistical analyses were performed
in Stata version 13.1 (StataCorpLP, USA). Univariable analy-
ses were performed by calculating odds ratios (ORs) by
assigning the presence of virulence genes as cases and absence
thereof as controls, and HUS as the outcome variable.
Virulence genes were considered significantly associated with
HUS if the p-value was <0.05. Significant factors were
analysed in a multivariable logistic regression model adjusted
for age group and Shiga toxin to calculate adjusted odds ratios
(aORs) with 95% confidence intervals (CIs).
Results
Description of cases
The description of cases (n = 333) and characteristics of iso-
lates (n = 334) from 1992 to 2012 have been published previ-
ously [5]. Briefly, the total number of cases was 339, with 190
females (56%) and median age 14 years (range <1 to 97). The
age distribution displayed two peaks, at age groups ≤5 years
(n = 134, 40%) and 21–40 years (n = 67, 20%). Half of the
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cases (n = 171, 50%) were non-import cases, 146 (43%) were
hospitalised and 31 (9%) were reported to have developed
HUS.
Serogroups and serotypes
A total of 340 isolates were typed into 24 different O
serogroups. The most frequent O serogroups included O157
(n = 115, 34%), O103 (n = 50, 15%), O26 (n = 34, 10%) and
O145 (n = 25, 7%). The most frequent serotypes included
O157:H7/H− (n = 115, 34%), O103:H2 (n = 47, 14%),
O26:H11 (n = 34, 10%) and O145:H28 (n = 18, 5%). Ten of
the O157 isolates (9%) were sorbitol fermenters.
Distribution of stx genes
A total of 218 isolates (64%) were positive for stx1 [stx1a
(n = 192), stx1c (n = 23), stx1d (n = 3)], 212 isolates (62%)
were positive for stx2 [stx2a (n = 90), stx2b (n = 32), stx2c
(n = 101), stx2d (n = 9), stx2g (n = 2)] and 91 isolates (43%)
were positive for both stx1 and stx2.
Distribution of toxins, adhesins and MRA
On average, isolates were positive for 15 virulence genes
(range: 1–24); two toxins (range: 0–4), five adhesins (range:
0–8) and eight MRA genes (range: 0–13). A total of 319
isolates (94%) were identified with toxin genes other than
stx1 and/or stx2. The most common toxin genes identified
were ehxA (n = 290), StcE/StcEO103 (n = 194) and subA
(n = 42). A total of 338 isolates (99%) were identified with
adhesion genes, most commonly IpfAO26 (n = 306), eae
(n = 252) and ihaA (n = 243). A total of 306 (90%) of the
isolates were identified with at least one MRA gene. The most
common genes identified were nleB (n = 250), Z2099
(n = 248), nleE and ent/espL2n (n = 247) (Table 1).
eae-positive (n = 252) and eae-negative (n = 88)
All eae-positive isolates were negative for aaiC and eibG, in
addition to the majority being negative for saa (n = 251), cnf
(n = 251), subA (n = 250) and astA (n = 248). All eae-negative
isolates were also negative for toxB and nleH1–2, in addition
to the majority being negative for cnf (n = 87), nleC (n = 86),
nleG2–3 (n = 86) and aaiC (n = 85). All HUS cases were
positive for eae.
O157:H7/H− (n = 115)
On average, O157:H7/H− isolates were positive for 21 viru-
lence genes (range: 9–24); two toxins (range: 1–4), seven
adhesins (range: 4–8) and 11 MRA (range: 0–13). All
O157:H7/H− isolates were positive for eae, Ipf1O157/OI-141
and Ipf2O157/OI-154. Conversely, none were positive for saa,
aaiC, IpfAO113, ehaA and subA. Major differences between
non-sorbitol-fermenting O157 (NSFO157) and SFO157 were
seen for ihaA, espP, toxB and ureC, which were absent from
all SFO157 (n = 10) and present in almost all NSFO157 (ihaA,
n = 105; espP, n = 95; toxB, n = 104; ureC, n = 101).
Conversely, cdtB I–IV was present in the majority of
SFO157 (n = 7, 70%) and in a minority of NSFO157 (n = 8,
8%). Among isolates from patients developing HUS of this
serotype (n = 12), all isolates were positive for IpfAO26 and all
were negative for eibG, astA, cnf, fyuA and pic. Differences
among the NSFO157 and SFO157 developing HUS were
seen for ihaA, agn43EDL933, espP and toxB, which were pres-
ent in all NSFO157 and absent from all SFO157.
O103:H2 (n = 47)
On average, O103:H2 isolates were positive for 13 virulence
genes (range: 11–17); two toxins (range: 1–3), three adhesins
(range: 2–7) and eight MRA (range: 6–9). All O103:H2
Table 1 Virulence genes present and absent in isolates from the four most frequent Shiga toxin-producing Escherichia coli (STEC) serotypes and
associated cases of haemolytic uraemic syndrome (HUS)




O157:H− 115 eae, Ipf1O157/OI-141,
Ipf2O157/OI-154
saa, aaiC, IpfAO113, ehaA, subA 12 IpfAO26 eibG, astA, cnf,
fyuA, pic
O103:H2 47 IpfAO26, ehaA, efa1/lifA,
Z2099, nleE, nleB
aaiC, toxB, IpfAO113, Ipf2O157/OI-154,
eibG, cnf, cdtB I–IV, nleH1–2, fyuA, pic
0
O26:H11 34 eae, iha1, IpfAO113, IpfAO26,
ehaA, efa1/lifA, ecf4, Z2099,
nleE, nleB, paa, fyuA,
ent/espL2n
saa, Ipf1O157/OI-141, Ipf2O157/OI-154,





O145:H28 18 iha1, agn43EDL933, Ipf1O157/OI-141,
IpfAO26, ehxA, efa1/lifA, Z2099,
nleB, nleE, paa, ureC,
ent/espL2n
saa, aaiC, toxB, IpfAO113, ehaA,
Ipf2O157/OI-154, eibG, astA, cnf,
cdtB I–IV, subA,
nleH1–2, fyuA, nleG2–3
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isolates were positive for IpfAO26, ehaA, efa1/lifA, Z2099,
nleE and nleB. Conversely, none of the isolates were positive
for aaiC, toxB, IpfAO113, Ipf2O157/OI-154, eibG, cnf, cdtB I–IV,
nleH1–2, fyuA and pic. All STEC O103:H2 carried stx1a and
none of these isolates were from cases that developed HUS.
O26:H11 (n = 34)
On average, O26:H11 isolates were positive for 19 virulence
genes (range: 16–20); one toxin (range: 1–2), seven adhesins
(range: 6–7) and 11MRA (range: 9–12). All O26:H11 isolates
were positive for eae, iha1, IpfAO113, IpfAO26, ehaA, efa1/lifA,
ecf4, Z2099, nleE, nleB, paa, fyuA and ent/espL2n, and all
were negative for saa, Ipf1O157/OI-141, Ipf2O157/OI-154, eibG,
toxB, astA, cnf, cdtB I–IV, subA, nleC and pic. Among isolates
from patients developing HUS of this serotype (n = 4), all
isolates were positive for agn43EDL933, ureC, nleH1–2 and
nleG2–3, and all were negative for pagC-like.
O145:H28 (n = 18) and O145:H? (n = 7)
On average, O145:H28 isolates were positive for 15 virulence
genes (range: 14–16); two toxins (range: 1–2), five adhesins
(range: 4–6) and eight MRA (range: 7–9). All O145:H28 iso-
lates were positive for iha1, agn43EDL933, Ipf1O157/OI-141,
IpfAO26, ehxA, efa1/lifA, Z2099, nleB, nleE, paa, ureC and
ent/espL2n, and all were negative for saa, aaiC, toxB,
IpfAO113, ehaA, Ipf2O157/OI-154, eibG, astA, cnf, cdtB I–IV,
subA, nleH1–2, fyuA and nleG2–3. One of the O145:H28
isolates was recovered from a case that developed HUS and
five O145:H? isolates were recovered from cases that devel-
oped HUS. All HUS isolates were positive for stx2a, IpfAO113
and nleH1–2, whereas all non-HUS isolates were negative.
Conversely, all isolates from HUS cases were negative for
iha1, agn43EDL933, Ipf1O157/OI-141 and StcE/StcEO103, whereas
all non-HUS isolates were positive.
Clusters and statistical associations
Analysis based on an UPGMA phylogeny dispersed the iso-
lates into diverse virulence gene combinations (Fig. 1).
Phylogenetic clusters of related isolates were seen within the
dominant serotypes, O157:H7/H−, O103:H2, O26:H11 and
O145:H28. Isolates from cases developing HUS were seen
distributed between multiple clusters, with certain clusters
appearing to be less commonly associated with HUS than
others. All isolates from HUS cases (n = 32) were positive
for eae and IpfAO26, and none were positive for saa, eibG,
astA, cnf, subA and pic. None of the isolates recovered from
cases aged between 20 and 60 years (n = 117), were serotyped
as O103:H2 (n = 47), positive for stx2b (n = 32), stx2d (n = 3),
stx2g (n = 2), stx1c (n = 23) or stx1d (n = 3), or recovered from
cases that developed HUS. Univariable analyses identified 11
virulence genes with a significant association with the devel-
opment of HUS in addition to age ≤5 years and stx2a
(Table 2). Multivariable analyses independent of serotype,
when adjusted for age group and presence of Stx, confirmed
age ≤5 years (aOR 12.7, 95% CI; 4.2–39), stx2a (aOR 28.6,
95% CI; 12.7–158) and the virulence gene nleH1–2 (aOR 8.4,
95% CI; 2.18–32.3) as independent risk factors for the devel-
opment of HUS (Table 2).
Discussion
Age (≤5 years) and the presence of an stx2a- and eae-positive
STEC have previously been identified as risk factors for the
development of HUS in several studies [4, 20–25]. In Norway,
these associations were confirmed in a recent study which
estimated the odds of developing HUS to be 16 times greater
for children aged 5 years or less (OR 16.7) and 30 times
greater for infections with stx2a-producing STEC (OR 30.1)
[5]. In the present study, we investigated the presence of 31
different virulence genes; five toxin genes, 12 adhesion genes
and 14 MRA-associated genes, in addition to eae, ehxA and
subtypes of stx1 and stx2, and their association with HUS
development.
Our results showed that the distribution and combina-
tion of virulence genes were clustered within distinct se-
rotypes, with cases of HUS dispersed among the different
virulent gene clusters. The largest accumulation and com-
bination of virulence genes was seen among isolates of
serotype O157:H−/H7. The combination of virulence
genes differed between NSFO157 and SFO157. We ob-
served, as demonstrated in previous studies, that the mo-
saic structure of OI-43 in SFO157 isolates lacked the iha1
and ureC genes [26]. Also, as seen in earlier studies, the
plasmid pO157-associated genes espA and toxB were ab-
sent from our SFO157 isolates [27]. The NSFO157 iso-
lates were mostly negative for cytolethal distending toxin
gene cdt (8%) compared to SFO157 isolates, which were
typically positive (70%). An association of cdt and HUS
among eae-negative non-SFO157 has previously been
suggested, although the association between cdt and
HUS in SFO157 is still unclear [28, 29]. Our results
showed that 67% of SFO157 isolates associated with
HUS were cdt-positive. Also, however, SFO157 isolates
not associated with HUS were positive for cdt (75%). In
addition to sorbitol fermentation, the presence of stx2a
was the marker with the highest positive predictive value
(PPV) for O157 association with HUS (29%). A single
NSFO157 isolate carried only an stx2c subtype of Stx
and was associated with HUS. This isolate displayed a
very different virulence gene profile to the other
NSFO157 isolates, and was the only isolate negative for
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nleC, ent/espL2n, pagC-like, nleG2–3, nleH1–2, ureC,
paa, nleB, ec4, efa1/lifA and StcE/StcEO103 (Fig. 1). Its
virulence gene combination suggested a low virulent
strain and it was supposed that unknown host factors
may have played an important role in the development
of HUS in this case. This was supported by the fact that
this STEC was isolated from a 66-year old-patient, who
was the only HUS patient above 12 years of age in the
study population.
The least number and combination of virulence genes among
the most frequent serotypes were observed for O103:H2 iso-
lates. Most O103:H2 isolates were grouped within two major
virulence gene clusters, separated only by the presence and
absence of agn43EDL933 and nleG2–3. nleG2–3 is encoded on
Fig. 1 Unweighted pair group method with arithmetic mean (UPGMA)
phylogenetic estimation of the relatedness of Shiga toxin-producing
Escherichia coli (STEC) isolates (n = 340) based on the absence or
presence of 33 virulence genes and subtypes of stx1 and stx2.
Phylogeny constructed using the majority summary method with 200
sample permutations. Branch intensity is according to descending
resampling support (light–dark). Global cophenetic correlation was esti-
mated to be 94%. Each node represents a unique combination of virulence
genes, with the size of the node correlating to the number of isolates with
that combination. Major serotypes are coloured according to the legend.
Isolates from cases developing haemolytic uraemic syndrome (HUS) are
indicated on the figure
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the pathogenicity island OI-57, which also encodes Z2099. As
previously shown, all O103:H2 isolates were positive for Z2099
[30], but only one of the two clusters was positive for nleG2–3.
Although the function of OI-57 is not entirely clear, OI-57 has
previously been demonstrated to be significantly associated
with human pathogenic STEC [8, 30, 31]. All O103:H25 iso-
lates in our collection were associated with HUS and positive
for stx2a, IpfAO113 and nleH1–2, whereas all O103:H2 isolates
were negative for these virulence factors. Furthermore, only two
of the O103:H2 isolates but all of the O103:H25 isolates (n = 3)
were positive for ureC and pagC-like [32].
Among the virulence genes screened, five were encoded on
the pathogenicity island OI-122 (efa1/lifA, ent/espL2n, nleB,
nleE, pagC-like). A complete OI-122 was seen in 98% of the
O157 isolates, with only two isolates negative for efa1/lifA.
Among the O103:H2 isolates, OI-122 genes efa1/lifA, ent/
espL2n, nle and nleE were seen to be co-located in 98% of
the isolates, with pagC-like being only present in two isolates.
An absent or truncated pagC may be an indicator for low vir-
ulence, as shown earlier [33]. The absence of pagC-like is also
evident in O26:H11 isolates, all of which were positive for all
other OI-122-associated genes. However, contrary to O103 iso-
lates, all O26:H11 isolates that were associated with HUS were
negative for pagC-like. In O26:H11 isolates, as seen for O157
isolates, stx2a was the marker with the highest PPV for associ-
ation with HUS (44%). Isolates of the O145 serogroup with an
H? phenotype were more frequently associated with HUS than
H28 (71% vs. 5%). Overall, our results indicated that the viru-
lence gene composition varies within each serotype, along with
the combination of virulence genes required for an HUS-
associated subtype (Supplemental Fig. 2).
In our univariable analysis, all of the OI-57 and OI-122
genes together with cdt, IpfAO113 and ureC, the plasmid-
encoded ecf4 (pO157) and the pathogenicity island OI-71 lo-
cated in nleH1–2 were seen to be significantly associated with
the development of HUS. However, in a multivariable logistic
regression model adjusted for age and stx2a, only nleH1–2
remained with a significant independent association with HUS
(aOR 8.4). nleH1–2 has previously been described as an im-
mune system modulator, functioning through inhibition of the
NF-KB activation [34, 35]. Studies have proposed that it likely
exhibits a role in the colonisation process rather than the attach-
ment and effacement phase of an STEC infection [36]. Its loca-
tion on OI-71 has been suggested to be an important discrimi-
nator, along with OI-122 for highly virulent enteropathogenic
Escherichia coli (EPEC) and STEC strains [8, 13, 18, 37].
The sensitivity of nleH1–2 in the detection of STEC isolates
recovered from HUS patients was estimated to be 91%, which
implied that only three isolates recovered from HUS patients
were negative for nleH1–2. Included in these isolates was the
stx2c-only NSFO157 isolate from a 66-year-old patient and an
O111 isolate recovered from an HUS patient with multi-strain
infection where one strain was nleH1–2-positive (carrying stx1a
and stx2a) and the other strain was negative (stx1a only).
Excluding these two isolates as probable non-HUS-associated,
the sensitivity of nleH1–2 increased to 97%, matching the sen-
sitivity of stx2a, although with a lower specificity (56% vs.
80%). The negative predictive value (NPV), when combining
age (≤5 years), eae, stx2a and nleH1–2, was estimated to be
97%, indicating that the likelihood of developing HUS was very
low if all these factors were negative. The PPV was estimated to
be 73%, which was an increase from 68% if we only considered
Table 2 Factors in STEC isolates
with a significant (p < 0.05)
association to the development of
HUS (n = 32) among STEC
infections in Norway 1992–2013
(n = 340)
Factor Cases exposed Controls exposed ORa p-Value aOR 95% CIb
n % n %
stx2a 29 90.6 61 19.8 39.1 <0.001 28.6 7.83–104
age ≤5 yearsc 27 84.4 108 35.1 10.0 <0.001 12.7 4.16–39.0
efa1/lifA 31 96.9 211 68.5 14.3 <0.01
paa 31 96.9 211 68.5 14.3 <0.01
ecf4 31 96.9 215 69.9 13.4 <0.01
nleE 31 96.9 216 70.1 13.2 <0.01
ent/espL2n 31 96.9 216 70.1 13.2 <0.01
nleB 31 96.9 219 71.1 12.6 <0.01
nleH1–2 29 90.6 135 43.8 12.4 <0.001 8.40 2.18–32.3
pagC-like 26 81.3 152 49.4 4.45 <0.01
Z2099 29 90.6 219 71.1 3.39 <0.05
nleG2–3 24 75.0 152 49.4 3.08 <0.01
lpfAO113 19 59.4 103 33.4 2.91 <0.01
aOR odds ratio
b aOR, 95% CI adjusted odds ratio with 95% confidence interval
c Host factor
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age (≤5 years), eae and stx2a. Also, the specificity increased
from 96 to 97% when including nleH1–2, allowing for a more
accurate exclusion of non-HUS-associated STEC. The matter of
concern was the low sensitivity (75%), which implied that 25%
of the STEC isolated from HUS patients in the current study did
not harbour this combination of risk factors. However, when
excluding the two probable non-HUS-associated isolates, the
sensitivity increased to 80%. Overall, the inclusion of nleH1–2
increased our probability of discerning HUS-associated STEC,
although other virulence factors and host-specific factors are
important when assessing patients at risk of developing HUS.
Our study was limited by the virulence genes selected and the
number of isolates tested. A methodological selection bias was
present for O157 due to diagnostic challenges and, consequently,
underreporting of non-O157 STEC. The low number of isolates
and HUS cases prevented a serotype-specific statistical HUS
association analysis. Furthermore, we only included STEC iso-
lates in our study, and the prevalence of these virulence genes in
other EPEC were not determined and, therefore, a direct associ-
ation to the development of HUS is likely an overestimation.
Also, we did not perform any gene expression analysis to con-
firm the level of gene translation. Lastly, data on host factors
other than age were not available to allow for adjustment in
our statistical model.
Our results showed that the non-LEE-encoded immune sys-
tem modulator nleH1–2, together with age ≤5 years and stx2a,
may contribute significantly in discerning HUS-associated
STEC (PPV 73%). The OR of developing HUS from an
STEC infectionwas eight times higher when stainswere positive
for nleH1–2. Larger studies are required to increase the statistical
power of the reported significant associations to enable a better
identification of HUS-associated STEC and review infection
control guidelines in light of new knowledge. We recommend
the Norwegian NRL to include screening for nleH1–2 in routine
STEC surveillance to improve the supervision of appropriate
infection control measures for sporadic cases and during STEC
outbreaks.
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